@article{8f91197c0e394b639afcb09b60967e52,
title = "Heart failure quality of care and in-hospital outcomes during the COVID-19 pandemic: findings from the Get With The Guidelines-Heart Failure registry",
abstract = "Aims: To assess heart failure (HF) in-hospital quality of care and outcomes before and during the COVID-19 pandemic.",
keywords = "COVID-19, Heart failure, Outcomes, Quality of care",
author = "Neil Keshvani and Anurag Mehta and Alger, {Heather M.} and Christine Rutan and Joseph Williams and Shuiaqi Zhang and Rebecca Young and Brooke Alhanti and Karen Chiswell and Greene, {Stephen J.} and DeVore, {Adam D.} and Yancy, {Clyde W.} and Fonarow, {Gregg C.} and Ambarish Pandey",
note = "Funding Information: The Get With The Guidelines{\textregistered}-Heart Failure (GWTG-HF) program is provided by the American Heart Association. GWTG-HF is sponsored, in part, by Novartis, Boehringer Ingelheim, Boehringer Ingelheim and Eli Lilly Diabetes Alliance, Novo Nordisk, Sanofi, AstraZeneca, Bayer, Tylenol and Alnylam Pharmaceuticals. Conflict of interest: S.J.G. has received research support from the Duke University Department of Medicine Chair's Research Award, American Heart Association, Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards for Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Roche Diagnostics, and Sanofi; and serves as a consultant for Amgen, Bayer, Bristol Myers Squibb, Merck, Sanofi and Vifor. A.D.D. has received research funding through his institution from the American Heart Association, Amgen, AstraZeneca, Bayer, Intra-Cellular Therapies, American Regent, the National Heart, Lung, and Blood Institute, Novartis, and the Patient-Centered Outcomes Research Institute; consults for Amgen, AstraZeneca, Bayer, CareDx, InnaMed, LivaNova, Mardil Medical, Novartis, Procyrion, scPharmaceuticals, Story Health, and Zoll; and has received nonfinancial support from Abbott for educational activities. G.C.F. has received consulting with Abbott, Amgen, AstraZeneca, Bayer, Edwards, Janssen, Merck, Medtronic, and Novartis. A.P. has received research funding from the Texas Health Resources Clinical Scholarship, Gilead Sciences Research Scholar Program, Applied Therapeutics (investigator-initiated grant), and National Institute of Aging (GEMSSTAR grant 1R03AG067960–01); and serves on the advisory board of Roche Diagnostics. All other authors have nothing to disclose. Funding Information: The Get With The Guidelines{\textregistered}‐Heart Failure (GWTG‐HF) program is provided by the American Heart Association. GWTG‐HF is sponsored, in part, by Novartis, Boehringer Ingelheim, Boehringer Ingelheim and Eli Lilly Diabetes Alliance, Novo Nordisk, Sanofi, AstraZeneca, Bayer, Tylenol and Alnylam Pharmaceuticals. Funding Information: S.J.G. has received research support from the Duke University Department of Medicine Chair's Research Award, American Heart Association, Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards for Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Roche Diagnostics, and Sanofi; and serves as a consultant for Amgen, Bayer, Bristol Myers Squibb, Merck, Sanofi and Vifor. A.D.D. has received research funding through his institution from the American Heart Association, Amgen, AstraZeneca, Bayer, Intra‐Cellular Therapies, American Regent, the National Heart, Lung, and Blood Institute, Novartis, and the Patient‐Centered Outcomes Research Institute; consults for Amgen, AstraZeneca, Bayer, CareDx, InnaMed, LivaNova, Mardil Medical, Novartis, Procyrion, scPharmaceuticals, Story Health, and Zoll; and has received nonfinancial support from Abbott for educational activities. G.C.F. has received consulting with Abbott, Amgen, AstraZeneca, Bayer, Edwards, Janssen, Merck, Medtronic, and Novartis. A.P. has received research funding from the Texas Health Resources Clinical Scholarship, Gilead Sciences Research Scholar Program, Applied Therapeutics (investigator‐initiated grant), and National Institute of Aging (GEMSSTAR grant 1R03AG067960–01); and serves on the advisory board of Roche Diagnostics. All other authors have nothing to disclose. Conflict of interest: Publisher Copyright: {\textcopyright} 2022 European Society of Cardiology.",
year = "2022",
month = jun,
doi = "10.1002/ejhf.2484",
language = "English (US)",
volume = "24",
pages = "1117--1128",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "6",
}